Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.34 |
| ▸ | OGFRL1 | Q5TC84 | 2/20 | 0.34 |
| ▸ | CTSB | P07858 | 3/20 | 0.34 |
| ▸ | CTSS | P25774 | 3/20 | 0.34 |
| ▸ | CTSL | P07711 | 2/20 | 0.34 |
| ▸ | CTSK | P43235 | 4/20 | 0.34 |
| ▸ | RORC | P51449 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL63621 | 0.95 | ROCK2 (0.38) | ADORA3ROCK2HPGDADORA2AADORA1 | |
| SCHEMBL61886 | 0.91 | HPGD (0.38) | ADORA3ROCK2HPGDADORA2AADORA1 | |
| SCHEMBL52246 | 0.90 | HPGD (0.37) | ADORA3ROCK2HPGDADORA2AADORA1 | |
| SCHEMBL62817 | 0.88 | ROCK2 (0.37) | ADORA3ROCK2HPGDADORA2AADORA1 | |
| SCHEMBL13691434 | 0.84 | ROCK2 (0.39) | ADORA3ROCK2HPGDADORA2AADORA1 | |
| SCHEMBL61903 | 0.84 | ROCK2 (0.36) | ADORA3ROCK2HPGDADORA2AADORA1 | |
| SCHEMBL52276 | 0.83 | ROCK2 (0.36) | ADORA3ROCK2HPGDADORA2AADORA1 | |
| SCHEMBL52427 | 0.82 | ADORA3 (0.36) | ADORA3HPGDOPRM1OPRD1OPRK1 | |
| SCHEMBL63048 | 0.81 | HPGD (0.36) | ROCK2HPGDCTSBCTSSCTSL | |
| SCHEMBL9905086 | 0.81 | HPGD (0.39) | ADORA3ROCK2HPGDADORA2AADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8129398-B2 | HIV integrase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-03-06 | — | — | US | disclosed |
| US-20090253677-A1 | HIV Integrase Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2009-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253677-A1 | HIV Integrase Inhibitors | DNTT, POLB, UNG | ADORA3 1885/4885ROCK2 1690/4885HPGD 1406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.